Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 9, 2025 • 12:31 PM ET

Date/Time Source News Release
06/05/2025 09:15 AM EDT GlobeNewswire Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
05/21/2025 08:55 AM EDT GlobeNewswire Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
05/16/2025 04:15 PM EDT GlobeNewswire Silo Pharma Announces Closing of $2 Million Public Offering
05/14/2025 04:07 PM EDT GlobeNewswire Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
05/14/2025 08:40 AM EDT GlobeNewswire Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
04/30/2025 08:11 AM EDT GlobeNewswire Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
04/28/2025 07:50 AM EDT GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
03/26/2025 08:40 AM EDT GlobeNewswire Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
02/26/2025 01:30 PM EST GlobeNewswire Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
02/18/2025 08:50 AM EST GlobeNewswire Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
Page